Inflarx N V's Cash & cash equivalent grew by 4.39 % in the Q4 2025 sequentially, while Current Liabilities decreased, this led to improvement in Inflarx N V's Quick Ratio to 3.22, above Inflarx N V average Quick Ratio.

Within Major Pharmaceutical Preparations industry 347 other companies have achieved higher Quick Ratio than Inflarx N V in fourth quarter 2025. While Quick Ratio total ranking in the fourth quarter 2025 has deteriorated compared to the prior quarter from to 1795.

Explain Quick Ratio?
How much Cash & cash equivalents IFRX�s has?
What are IFRX�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/IFRX/financial-strength

https://api.csimarket.com/api/v1/companies/IFRX/fundamentals

https://api.csimarket.com/api/v1/companies/IFRX/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

IFRX Quick Ratio	(Dec 31 2025) Q4	0 Q3	0 Q2	0 Q1	(Dec 31 2024) Q2
Y / Y Current Liabilities Change	-56.79 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	-1.99 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	3.22	Subscribe	Subscribe	Subscribe	Subscribe
IFRX's Total Ranking	# 1795	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	-56.42 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	4.39 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio fourth quarter 2025 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 348
Healthcare Sector	# 629
Overall Market	# 1795

Quick Ratio Statistics
High	Average	Low
1.36	1.23	0.98
(Dec 31 2022)		(Dec 31 2023)

Financial Statements
Inflarx N V's Current Liabilities	$ 6 Millions	Visit IFRX's Balance sheet
Inflarx N V's Cash & cash equivalent	$ 20 Millions	Visit IFRX's Balance sheet
Source of IFRX's Sales		Visit IFRX's Sales by Geography

Cumulative Inflarx N V's Quick Ratio

IFRX's Quick Ratio for the trailling 12 Months

IFRX Quick Ratio	(Dec 31 2025) 12 Months	0 12 Months	0 12 Months	0 12 Months	(Dec 31 2024) 12 Months
Y / Y Current Liabilities TTM Growth	-34.79 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	-1.39 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	1.58	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 1282	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	-14.29 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	-0.52 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to IFRX Financial Strength Comparisons >> Go to Compare IFRX Quick Ratio to its Competitors

On the trailing twelve months basis Current Liabilities decreased faster than Inflarx N V's average Cash & cash equivalent, this led to increase in in Inflarx N V's Quick Ratio to 1.58, Quick Ratio remained below IFRX average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 483 other companies have achieved higher Quick Ratio than Inflarx N V. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2025 from to 4635.

Explain Quick Ratio?
How much Cash & cash equivalents IFRX�s has?
What are IFRX�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 484
Healthcare Sector	# 989
Within the Market	#

trailing twelve months Quick Ratio Statistics
High	Average	Low
7.14	2.37	0.76
(Dec 31 2018)		(Dec 31 2023)

Companies with similar Quick Ratio in the quarter ending Dec 31 2025, within Major Pharmaceutical Preparations Industry	Quick Ratio	Dec 31 2025 MRQ Cash & cash equivalent	Dec 31 2025 MRQ Current Liabilities
Enanta Pharmaceuticals Inc	8.73	$ 390.316 Millions	$ 44.728 Millions
Moonlake Immunotherapeutics	8.66	$ 393.968 Millions	$ 45.478 Millions
Boundless Bio Inc	8.58	$ 107.581 Millions	$ 12.537 Millions
Corbus Pharmaceuticals Holdings Inc	8.57	$ 163.269 Millions	$ 19.059 Millions
Opus Genetics Inc	8.53	$ 45.091 Millions	$ 5.285 Millions
Anaptysbio Inc	8.53	$ 311.638 Millions	$ 36.545 Millions
Telomir Pharmaceuticals Inc	8.52	$ 7.287 Millions	$ 0.855 Millions
Polaryx Therapeutics Inc	8.50	$ 5.143 Millions	$ 0.605 Millions
Gyre Therapeutics Inc	8.40	$ 184.631 Millions	$ 21.978 Millions
Cartesian Therapeutics Inc	8.38	$ 125.139 Millions	$ 14.937 Millions
Context Therapeutics Inc	8.35	$ 65.995 Millions	$ 7.908 Millions
Evommune Inc	8.33	$ 149.200 Millions	$ 17.909 Millions
Adagene Inc	8.25	$ 75.844 Millions	$ 9.199 Millions
Theravance Biopharma inc	8.23	$ 315.357 Millions	$ 38.302 Millions
BlossomHill Therapeutics, Inc.	8.17	$ 136.682 Millions	$ 16.728 Millions
Medicinova Inc	8.11	$ 30.806 Millions	$ 3.798 Millions
Adc Therapeutics Sa	8.11	$ 261.338 Millions	$ 32.230 Millions
Abcellera Biologics Inc	7.98	$ 405.313 Millions	$ 50.781 Millions
Coya Therapeutics Inc	7.97	$ 46.823 Millions	$ 5.872 Millions
Lite Strategy Inc	7.85	$ 8.758 Millions	$ 1.115 Millions
Atea Pharmaceuticals Inc	7.75	$ 301.830 Millions	$ 38.941 Millions
Shattuck Labs Inc	7.68	$ 54.192 Millions	$ 7.052 Millions
Scynexis Inc	7.62	$ 40.031 Millions	$ 5.251 Millions
Avalo Therapeutics Inc	7.60	$ 98.373 Millions	$ 12.940 Millions
Milestone Pharmaceuticals Inc	7.58	$ 105.960 Millions	$ 13.979 Millions
Acrivon Therapeutics Inc	7.57	$ 118.582 Millions	$ 15.664 Millions
Annovis Bio Inc	7.54	$ 19.532 Millions	$ 2.591 Millions
Newamsterdam Pharma Company N v	7.40	$ 636.241 Millions	$ 86.036 Millions
Adicet Bio Inc	7.36	$ 158.530 Millions	$ 21.531 Millions
Novabridge Biosciences	7.33	$ 210.842 Millions	$ 28.781 Millions

Date modified: 2026-10-05T11:03:39+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.